<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>340</serviceExecutionTime><Drug id="53599"><DrugName>PS-388023</DrugName><DrugSynonyms><Name><Value>PS-388023</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>angiogenesis inhibitors (inflammatory/ocular/oncological indications), Pharmacopeia</Value></Name><Name><Value>dual integrin alpha-5/beta-3 + alpha-5/beta-5 inhibitors (inflammatory/ocular/oncological indications), Pharmacopeia</Value></Name><Name><Value>PS-680648</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PS-780035</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>angiogenesis inhibitors (ocular indications), Pharmacopeia/Allergan</Value></Name><Name><Value>dual integrin avb3/avb5 inhibitors (inflammatory/ocular/oncological indications), Pharmacopeia</Value></Name></DrugSynonyms><CompanyOriginator id="19062">Pharmacopeia Inc</CompanyOriginator><CompaniesSecondary><Company id="14042">Allergan Inc</Company><Company id="19062">Pharmacopeia Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="53599" type="Drug"><TargetEntity id="442499" type="siDrug">PS-388023</TargetEntity></SourceEntity><SourceEntity id="14042" type="Company"><TargetEntity id="5000014741" type="organizationId">Allergan Inc</TargetEntity></SourceEntity><SourceEntity id="19062" type="Company"><TargetEntity id="4295907284" type="organizationId">Pharmacopeia Inc</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="239" type="ciIndication"><TargetEntity id="10015916" type="MEDDRA"></TargetEntity><TargetEntity id="D005128" type="MeSH"></TargetEntity><TargetEntity id="-2056365523" type="omicsDisease"></TargetEntity><TargetEntity id="754" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2458" type="Action"><TargetEntity id="1605" type="Mechanism">Anti-CD51/CD61 (Integrin alphavbeta3)</TargetEntity><TargetEntity id="863" type="Mechanism">Integrin alphavbeta3 (Vitronectin) Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-01147" type="ciTarget"><TargetEntity id="57551" type="siTarget">Integrin alphavbeta3 (vitronectin) receptor</TargetEntity></SourceEntity><SourceEntity id="PTGT-01149" type="ciTarget"><TargetEntity id="57561" type="siTarget">Integrin alphavbeta5 receptor</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication><Indication id="239">Ocular disease</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="2459">Integrin alpha-V/beta-5 antagonist</Action><Action id="2458">Integrin alpha-V/beta-3 antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="61">Angiogenesis inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-16T09:17:51.000Z</LastModificationDate><ChangeDateLast>2009-05-29T15:56:37.000Z</ChangeDateLast><AddedDate>2005-07-18T17:23:44.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19062" linkType="Company"&gt;Pharmacopeia&lt;/ulink&gt;, and licensee for ocular indications &lt;ulink linkID="14042" linkType="Company"&gt;Allergan&lt;/ulink&gt;,  were investigating the anti-angiogenic PS-388023, an inhibitor of integrin alpha-v/beta-3 and alpha-v/beta-5, for the potential treatment of immunological and oncological indications [&lt;ulink linkID="579752" linkType="Reference"&gt;579752&lt;/ulink&gt;], [&lt;ulink linkID="602127" linkType="Reference"&gt;602127&lt;/ulink&gt;], and  ocular indications such as age-related macular degeneration [&lt;ulink linkID="601922" linkType="Reference"&gt;601922&lt;/ulink&gt;], [&lt;ulink linkID="611925" linkType="Reference"&gt;611925&lt;/ulink&gt;]. In May 2005, preclinical optimization studies were underway [&lt;ulink linkID="602127" linkType="Reference"&gt;602127&lt;/ulink&gt;]. By December 2005,   preclinical studies  were ongoing and Pharmacopeia was seeking to outlicense the program for oncological indications [&lt;ulink linkID="649954" linkType="Reference"&gt;649954&lt;/ulink&gt;],  [&lt;ulink linkID="648222" linkType="Reference"&gt;648222&lt;/ulink&gt;]; however,  in January 2008, the company confirmed that this program had been discontinued in the first quarter of 2007 [&lt;ulink linkID="869988" linkType="Reference"&gt;869988&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By May 2005, preclinical studies had shown that PS-388023 simultaneously inhibited integrin alpha-v/beta-3 and alpha-v/beta-5, with an IC50 of less than 1 nM in integrin binding assays. The compound also blocked FGF and VEGF induced human endothelial cell proliferation (IC50 &amp;lt; 100 nM), inhibited vitronectin-induced endothelial cell transwell migration (IC50 = 10 nM), and inhibited corneal and retinal neovascularization in rodent models [&lt;ulink linkID="601922" linkType="Reference"&gt;601922&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 2005, Allergan entered an agreement to evaluate Pharmaceopia's angiogenesis inhibitors for ocular diseases [&lt;ulink linkID="611925" linkType="Reference"&gt;611925&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19062">Pharmacopeia Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2007-03-31T00:00:00.000Z</StatusDate><Source id="869988" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19062">Pharmacopeia Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="239">Ocular disease</Indication><StatusDate>2007-03-31T00:00:00.000Z</StatusDate><Source id="869988" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19062">Pharmacopeia Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="188">Inflammatory disease</Indication><StatusDate>2007-03-31T00:00:00.000Z</StatusDate><Source id="869988" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="239">Ocular disease</Indication><StatusDate>2007-03-31T00:00:00.000Z</StatusDate><Source id="869988" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19062">Pharmacopeia Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="239">Ocular disease</Indication><StatusDate>2005-05-05T00:00:00.000Z</StatusDate><Source id="602127" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19062">Pharmacopeia Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2005-05-05T00:00:00.000Z</StatusDate><Source id="602127" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19062">Pharmacopeia Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-05-05T00:00:00.000Z</StatusDate><Source id="602127" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14042">Allergan Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="239">Ocular disease</Indication><StatusDate>2005-07-12T00:00:00.000Z</StatusDate><Source id="611925" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01147"><Name>Integrin alpha-V/beta-3</Name><SwissprotNumbers><Swissprot>O54890</Swissprot><Swissprot>P05106</Swissprot><Swissprot>P06756</Swissprot><Swissprot>P26008</Swissprot><Swissprot>P43406</Swissprot><Swissprot>P80746</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01149"><Name>Integrin alpha-V/beta-5</Name><SwissprotNumbers><Swissprot>O70309</Swissprot><Swissprot>P06756</Swissprot><Swissprot>P18084</Swissprot><Swissprot>P26008</Swissprot><Swissprot>P43406</Swissprot><Swissprot>P80746</Swissprot><Swissprot>Q07441</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1088700">Allergan plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17808">Ligand Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="108055" title="Allergan to develop Pharmacopeia's PS-388023 and angiogenesis inhibitors for AMD"/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>